16417-22-4 Usage
Molecular structure
2-[(1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)methyl]-1H-isoindole-1,3(2H)-dione has a complex molecular structure, featuring a benzothiazole moiety and an isoindole-1,3-dione group.
Benzothiazole moiety
The compound contains a benzothiazole ring, which is a heterocyclic aromatic ring consisting of a benzene ring fused to a thiazole ring (a five-membered ring with one sulfur and one nitrogen atom).
Isoindole-1,3-dione group
The compound also features an isoindole-1,3-dione group, which is a derivative of isoindole with two oxygen atoms double-bonded to the first and third carbon atoms of the isoindole core.
Potential applications
Due to its unique structure and properties, 2-[(1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)methyl]-1H-isoindole-1,3(2H)-dione may have potential pharmaceutical or industrial applications.
Further research needed
To fully understand the potential uses and effects of this compound, additional research and analysis are required. This may include studying its chemical reactivity, stability, and interactions with other substances or biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 16417-22-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,4,1 and 7 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 16417-22:
(7*1)+(6*6)+(5*4)+(4*1)+(3*7)+(2*2)+(1*2)=94
94 % 10 = 4
So 16417-22-4 is a valid CAS Registry Number.
16417-22-4Relevant articles and documents
Design, synthesis and evaluation of N-substituted saccharin derivatives as selective inhibitors of tumor-associated carbonic anhydrase XII
D'Ascenzio, Melissa,Carradori, Simone,De Monte, Celeste,Secci, Daniela,Ceruso, Mariangela,Supuran, Claudiu T.
, p. 1821 - 1831 (2014/03/21)
A series of N-alkylated saccharin derivatives were synthesized and tested for the inhibition of four different isoforms of human carbonic anhydrase (CA, EC 4. 2.1.1): the transmembrane tumor-associated CA IX and XII, and the cytosolic CA I and II. Most of the reported derivatives inhibited CA XII in the nanomolar/low micromolar range, hCA IX with KIs ranging between 11 and 390 nM, whereas they were inactive against both CA I (KIs >50 μM) and II (KIs ranging between 39.1 nM and 50 μM). Since CA I and II are off-targets of antitumor carbonic anhydrase inhibitors (CAIs), the obtained results represent an encouraging achievement for the development of new anticancer candidates without the common side effects of non-selective CAIs. Moreover, the lack of an explicit zinc binding function on these inhibitors opens the way towards the exploration of novel mechanisms of inhibition that could explain the high selectivity of these compounds for the inhibition of the transmembrane, tumor-associated isoforms over the cytosolic ones.
